Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 479.00 | |
5 mg | In stock | $ 1,080.00 | |
25 mg | In stock | $ 1,720.00 | |
50 mg | In stock | $ 2,180.00 | |
100 mg | In stock | $ 2,780.00 |
Description | KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI). |
Molecular Weight | 334.33 |
Formula | C19H14N2O4 |
CAS No. | 1952276-71-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KCL-286 1952276-71-9 Metabolism Retinoid Receptor inhibitor inhibit